Regulus Therapeutics Inc.
RGLS
주식 순위
#17280
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
주가
$8.16
마지막 동기화: 2025-06-26
시가총액
$234.57M
변동 (1일)
0.00%
변동 (1년)
-56.96%
국가
US
거래 Regulus Therapeutics Inc. (RGLS)
카테고리
Healthcare
Regulus Therapeutics Inc. (RGLS)의 주가 이력
최고 종가: $18.90 (2024-08-01 기준)
최저 종가: $25.97 (2018-04-01 기준)
최저 종가: $25.97 (2018-04-01 기준)
Regulus Therapeutics Inc.의 주가 이력 (2018 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2024 | 115.52% |
| 2023 | 128.77% |
| 2022 | -59.49% |
| 2021 | -66.20% |
| 2020 | -18.96% |
| 2019 | 28.12% |
| 2018 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
